

Financial news for VICL dated on 2019-08-30: Vical Stockholders Approve Reverse Stock Split and Merger with Brickell

Financial news for VICL dated on 2019-08-30: Vical Announces Approval For Merger With Brickell

Financial news for VICL dated on 2019-08-30: 18 Healthcare Stocks Moving In Friday's Pre-Market Session

Financial news for VICL dated on 2019-08-29: 23 Healthcare Stocks Moving In Thursday's Pre-Market Session

Financial news for VICL dated on 2019-08-13: 16 Healthcare Stocks Moving In Tuesday's Pre-Market Session

Financial news for VICL dated on 2019-08-12: 17 Healthcare Stocks Moving In Monday's Pre-Market Session

Financial news for VICL dated on 2019-08-07: 42 Healthcare Stocks Moving In Wednesday's After-Market Session

Financial news for VICL dated on 2019-07-30: 33 Healthcare Stocks Moving In Today's Pre-Market Session

Financial news for VICL dated on 2019-06-04: 66 Biggest Movers From Yesterday

Financial news for VICL dated on 2019-06-03: A Look At Benzinga Pro's Most-Searchd Tickers For June 3, 2019

Financial news for VICL dated on 2019-06-03: 51 Stocks Moving In Monday's Mid-Day Session

Financial news for VICL dated on 2019-06-03: Benzinga Pro's Top 10 Most-Searchd Tickers For Morning of Mon., June 3, 2019

Financial news for VICL dated on 2019-06-03: 30 Stocks Moving In Monday's Pre-Market Session

Financial news for VICL dated on 2019-06-03: A Peek Into The Markets: US Stock Futures Signal Lower Start On Wall Street

Financial news for VICL dated on 2019-06-03: 5 Stocks To Watch For June 3, 2019

Financial news for VICL dated on 2019-06-03: Vical and Brickell Announce Merger Agreement in All-Stock Deal

Financial news for VICL dated on 2019-02-25: H.C. Wainwright Downgrades Vical to Neutral

Financial news for VICL dated on 2019-02-19: Vical Shares To Resume Trade At 6:15 p.m. EST

Financial news for VICL dated on 2019-02-19: Vical Says Will Undertake Restructuring, Sees Restructuring-Related Charge In Q1'19

Financial news for VICL dated on 2019-02-19: Vical Q4 EPS \$(0.17) Up From \$(0.21) YoY, Sales \$124K Down From \$3.953M YoY

Financial news for VICL dated on 2019-02-19: Vical Reports Will Discontinue Development Of VL-2397, Will Consider Near-Term Strategic Alternatives

Financial news for VICL dated on 2019-02-19: Vical Shares Halted News Pending

Financial news for VICL dated on 2018-10-29: Vical Incorporated Q3 EPS \$(0.07) Beats \$(0.22) Estimate, Sales \$47K Miss \$180K Estimate

Financial news for VICL dated on 2018-08-07: Vical Q2 EPS \$(0.22) Beats \$(0.27) Estimate, Sales \$735K Beat \$310K Estimate

Financial news for VICL dated on 2018-07-19: Vical Reports Review of Potential Strategic Transactions, Says They Anticipate Ending 2018 With \$40M In Cash Absent Of Any Transaction Which Would Fund Operations Of Top-Line Data From Its Phase 2 Program Expected 2020

Financial news for VICL dated on 2018-06-15: Benzinga's Biggest Movers For The Week Of June 11, 2018

Financial news for VICL dated on 2018-06-13: Vical 10%+ Owner Steven Boyd Steven Buys 670,897 @ Avg Price: \$1.16

Financial news for VICL dated on 2018-06-12: 44 Biggest Movers From Yesterday

Financial news for VICL dated on 2018-06-11: Mid-Afternoon Market Update: Dow Rises 80 Points; Nano Dimension Shares Spike Higher

Financial news for VICL dated on 2018-06-11: 32 Stocks Moving In Monday's Mid-Day Session

Financial news for VICL dated on 2018-06-11: Mid-Day Market Update: RF Industries Climbs After Q2 Results; Vical Shares Slide

Financial news for VICL dated on 2018-06-11: Vical Shares Down 28.5% After Co. Reported Phase 2 Trial Of HSV-2 Therapeutic Vaccine For Genital Herpes Did Not Meet Primary Endpoint; Co. Announced It Would Be Terminating HSV-2 Program And Will Remain Focused On Antifungal VL-2397

Financial news for VICL dated on 2018-06-11: Vical Reports Phase 2 Trial Of HSV-2 Therapeutic Vaccine Did Not Meet Primary Endpoint

Financial news for VICL dated on 2018-05-03: Vical Q1 EPS \$(0.29) Misses \$(0.09) Estimate, Sales \$716K Miss \$2.1M Estimate

Financial news for VICL dated on 2018-03-15: Vical Reports Q4 EPS \$(0.21) vs \$(0.11) Est., Sales \$4M vs \$4.08M Est.

Financial news for VICL dated on 2018-02-12: Vical 13G Filing From Eventide Asset Mgmt. Shows New 9.1% Stake

Financial news for VICL dated on 2018-02-01: Vical and Mycoses Study Group Education and Research Consortium Establish Collaboration to Advance Vical's Novel Antifungal VL-2397 for the Treatment of Invasive Aspergillosis

Financial news for VICL dated on 2018-01-30: Vical Shares Resume Trade, Up 1.4%

Financial news for VICL dated on 2018-01-30: Vical Shares To Resume Trade At 4:45 p.m. EST

Financial news for VICL dated on 2018-01-30: Vical Sees Incurring Personnel-Related Restructuring Charges ~\$1.1M In Q1'18

Financial news for VICL dated on 2018-01-30: Vical Sees '17 Cash Burn At Low End Of \$8M-\$11M Outlook

Financial news for VICL dated on 2018-01-30: Vical Reports Restructuring Aimed At Focus On Resources For HSV-2, Antifungal Clinical Programs

Financial news for VICL dated on 2018-01-30: Vical Shares Halted News Pending

Financial news for VICL dated on 2018-01-22: Astellas, Vical Announce Phase 3 Trial of Cytomegalovirus Vaccine ASP0113 in Hematopoietic Stem Cell Transplant Recipients Did Not Meet Primary, Secondary Endpoints

Financial news for VICL dated on 2017-11-20: Vical 13G Filing From Armistice Capital Shows New 9.2% Stake

Financial news for VICL dated on 2017-11-15: Stonepine Capital Management Reports 6.6% Passive Stake in Vical -13G

Financial news for VICL dated on 2017-11-14: Vical Director Merton Buys 85,700 @ Avg Price: \$1.75 -Form4

Financial news for VICL dated on 2017-11-09: 57 Biggest Movers From Yesterday

Financial news for VICL dated on 2017-11-08: 46 Stocks Moving In Wednesday's Mid-Day Session

Financial news for VICL dated on 2017-11-08: 32 Stocks Moving In Wednesday's Pre-Market Session

Financial news for VICL dated on 2017-11-08: Vical Prices ~14.286M Share Common Stock Offering At \$1.75/Share

Financial news for VICL dated on 2017-11-07: 40 Biggest Movers From Yesterday

Financial news for VICL dated on 2017-10-24: 30 Stocks Moving In Tuesday's Pre-Market Session

Financial news for VICL dated on 2017-10-24: Vical Announces Collaboration with AnGes

on a Treatment for Chronic Hepatitis B Infection

Financial news for VICL dated on 2017-10-23: Fical Q3 EPS \$(0.27) vs \$(0.25) Est., Sales \$3.24M vs \$3.77M Est.

Financial news for VICL dated on 2017-10-18: 32 Biggest Movers From Yesterday

Financial news for VICL dated on 2017-10-17: 30 Stocks Moving In Tuesday's Mid-Day Session

Financial news for VICL dated on 2017-10-17: 25 Stocks Moving In Tuesday's Pre-Market Session

Financial news for VICL dated on 2017-10-16: Vical Files S-1 For \$23M Stock Offering

Financial news for VICL dated on 2017-10-10: Benzinga's Option Alert Recap From October 10

Financial news for VICL dated on 2017-10-10: Vical Option Alert: Mar 16 \$4 Calls Sweep (2) at the Ask: 1000 @ \$0.426 vs 205 OI; Ref=\$3.02

Financial news for VICL dated on 2017-10-10: 25 Stocks Moving In Tuesday's Pre-Market Session

Financial news for VICL dated on 2017-10-10: Vical Reports Closing Of Phase 3 ASP0113 CMV Vaccine Trial

Financial news for VICL dated on 2017-10-03: Mid-Afternoon Market Update: Tile Shop Drops On Weak Sales Forecast; Endocyte Shares Spike Higher

Financial news for VICL dated on 2017-10-03: 15 Biggest Mid-Day Gainers For Tuesday

Financial news for VICL dated on 2017-10-03: Vical Shares Up 25.91% Just Ahead Of Today's Conference Call; Co. Announced After-hours Monday Receipt Of FDA Approval For VL-2397 For Limited Use Indication

Financial news for VICL dated on 2017-10-03: Mid-Morning Market Update: Markets Open Higher; Paychex Profit Beats Estimates

Financial news for VICL dated on 2017-10-03: Vical Will Hold Conf. Call On VL-2397 FDA Approval at 12noon ET Today

Financial news for VICL dated on 2017-10-03: 18 Stocks Moving In Tuesday's Pre-Market Session

Financial news for VICL dated on 2017-10-02: Vical Announces VL-2397 Approval By FDA For Limited Use Indication

Financial news for VICL dated on 2017-08-08: Vical Q2 EPS \$(0.30) vs \$(0.26) Est., Sales \$3.42M vs \$3.42M Est.

Financial news for VICL dated on 2017-06-12: Rodman & Renshaw Assumes Vical at Buy, Announces price target \$9.00

Financial news for VICL dated on 2017-06-05: Vical Says Phase 2 of VL-2397 is Planned for Q4 2017, Gives Update

Financial news for VICL dated on 2017-06-01: 8-K from Vical Shows Chief Accounting Officer, Anthony Ramos, Named CFO

Financial news for VICL dated on 2017-05-15: Vical Q1 EPS \$(0.25) vs \$(0.18) Est, Sales \$3.21M vs \$4.66M Est

Financial news for VICL dated on 2017-04-05: 18 Biggest Mid-Day Gainers For Wednesday

Financial news for VICL dated on 2017-04-05: 25 Stocks Moving In Wednesday's Pre-Market Session

Financial news for VICL dated on 2017-04-04: Vical Shares Up ~14-15% Following 8-K Showing Co. Entered Research Collaboration Deal with AnGes MG, No Terms Disclosed

Financial news for VICL dated on 2017-03-09: Vical Reports Q4 EPS \$(0.25) vs \$(0.21) Est., Sales \$3.2M vs \$3.9M Est.

Financial news for VICL dated on 2016-11-03: Vical Q3 EPS \$(0.24) vs \$(0.25) Est, Revenue \$2.64M vs \$4.60M Est

Financial news for VICL dated on 2016-09-26: Vical Initiates Phase 2 Trials for Genital Herpes Vaccine

Financial news for VICL dated on 2016-09-19: Mid-Afternoon Market Update: NASDAQ Turns Lower; Isle of Capri Casinos Shares Surge Following Merger News

Financial news for VICL dated on 2016-09-19: 8 Biggest Mid-Day Losers For Monday

Financial news for VICL dated on 2016-09-19: Mid-Day Market Update: Crude Oil Up 2%; Sarepta Therapeutics Shares Spike Higher

Financial news for VICL dated on 2016-09-19: Mid-Morning Market Update: Markets Open Higher; Tech Data To Buy Technology Solutions From Avnet

Financial news for VICL dated on 2016-09-19: 15 Stocks Moving In Monday's Pre-Market Session

Financial news for VICL dated on 2016-09-19: Vical Phase 2 Trial Does Not Meet Primary Endpoint

Financial news for VICL dated on 2016-08-09: Vical Q2 EPS (\$0.14) vs (\$0.28) est, Revenue \$4.12M vs \$4.49M est

Financial news for VICL dated on 2016-08-01: Vical Announces \$7.8M Private Placement at \$4.24/Share

Financial news for VICL dated on 2016-07-19: Benzinga's Top Initiations

Financial news for VICL dated on 2016-07-19: H.C. Wainwright Assumes Vical at Buy, Announces \$12.00 PT

Financial news for VICL dated on 2016-06-20: UPDATE: Vical Maintains Net Cash Burn Guidance \$8M-\$11M for '16

Financial news for VICL dated on 2016-06-20: UPDATE: Vical Says 'Vical plans to advance the bivalent vaccine to a Phase 2 trial in 2016 and maintains current financial guidance for 2016'

Financial news for VICL dated on 2016-06-20: Vical Reports Phase 1/2 Trial Data Showed Bivalent Vaccine Imparts Reduction in Herpes Lesions Durable to Nine Months

Financial news for VICL dated on 2016-06-13: Vical to Present HSV-2 Phase 1/2 Data at June ASM Microbe/ICAAC 2016 Conference

Financial news for VICL dated on 2016-06-08: Vical Spikes to High of \$4.43 on Vol

Financial news for VICL dated on 2016-06-08: Director Douglas Jr Buys 10,078 Shares of Vical @\$4.41/Share -Form 4

Financial news for VICL dated on 2016-05-27: 5 Gainers And Losers In The Pre-Market Today

Financial news for VICL dated on 2016-05-09: Vical Q1 EPS (\$0.03) vs (\$0.04) est, Revenue \$4.6M vs \$6.9M est

Financial news for VICL dated on 2016-03-30: Vical Announces FDA Granted Fast Track Designation for VL-2397 for Treatment of Invasive Aspergillosis

Financial news for VICL dated on 2016-03-14: Vical Q4 PES (\$0.03) vs \$0.10 est, Revenue \$6.81M vs \$4.66M est, May Not Compare

Financial news for VICL dated on 2016-03-14: Earnings Scheduled For March 14, 2016

Financial news for VICL dated on 2016-03-07: Vical Announces Initiation of Phase 1 Trial for VL-2397

Financial news for VICL dated on 2016-01-06: Vical Announces FDA Has Granted Orphan Drug Designation for VL-2397 for Treatment of Invasive Aspergillosis

Financial news for VICL dated on 2015-10-29: Vical Q3 PES \$0.00 vs -\$0.04 est, Revenue \$5M vs \$3.4M est

Financial news for VICL dated on 2015-08-19: Vical Announces FDA Has Granted Qualified Infectious Disease Product Designation to VL-2397

Financial news for VICL dated on 2015-07-30: Vical Inc Reports Q2 Loss \$0.03 Vs Est Loss \$0.06, Sales \$4.18M Vs Est \$3.80M

Financial news for VICL dated on 2015-07-21: Stocks Hitting 52-Week Lows

Financial news for VICL dated on 2015-06-23: Roth Capital Downgrades Vical to

Neutral, Lowers PT to \$1.65

Financial news for VICL dated on 2015-06-23: Stocks Hitting 52-Week Lows

Financial news for VICL dated on 2015-06-23: Morning Market Losers

Financial news for VICL dated on 2015-06-22: Shares of Vical Trading Down ~43% Following Resumption

Financial news for VICL dated on 2015-06-22: Shares of Vical to Resume Trade at 4:40 p.m. EDT

Financial news for VICL dated on 2015-06-22: Vical Reports Top-Line Results From Phase 1/2 Trial of Therapeutic Genital Herpes Vaccine, Primary Endpoint Not Met

Financial news for VICL dated on 2015-06-22: Vical Shares Halted News Pending

Financial news for VICL dated on 2015-06-19: Vical Files Up to \$100M Mixed Shelf

Financial news for VICL dated on 2015-06-12: HC Wainwright Initiates Coverage on Vical at Buy, Announces \$2.50 PT

Financial news for VICL dated on 2015-06-02: Morning Market Gainers

Financial news for VICL dated on 2015-06-02: Benzinga's Top #PreMarket Gainers

Financial news for VICL dated on 2015-06-02: Vical Shares Rise 10% Premarket Following Initiation at Roth With Buy, \$4.65 PT

Financial news for VICL dated on 2015-06-02: Roth Capital Initiates Coverage on Vical at Buy, Announces \$4.65 PT

Financial news for VICL dated on 2015-06-02: Roth Initiates Coverage on Vical at Buy, Announces \$4.65 PT

Financial news for VICL dated on 2015-05-21: Vical Announces Completion of Enrollment in Phase 2 Clinical Trial of Investigational CMV Vaccine in Kidney Transplant Recipients

Financial news for VICL dated on 2015-05-08: Vical Posts Q1 Net Loss

Financial news for VICL dated on 2015-05-08: Vical Inc Q1 EPS -\$0.04 vs -\$0.05 est, Revenue \$4.9M vs \$2.5M est

Financial news for VICL dated on 2015-04-22: Vical Announces \$4M Contract to Manufacture HIV-antigen Plasmid DNA

Financial news for VICL dated on 2015-04-21: Vical Presents Preclinical Data for Congenital CMV DNA Vaccine at International Conference

Financial news for VICL dated on 2015-03-25: Vical Expands Portfolio With Noval Antifungal From Astellas, 2015 Cash Burn Remains Unchanged, Targeting Phase 1 Initiation In H1 2016

Financial news for VICL dated on 2015-02-26: Vical Inc Reports Inline Q4 EPS -\$0.05, Sales \$4.82M Vs Est \$2.79M

Financial news for VICL dated on 2015-02-04: Vical Being Mentioned as Measles Play

Financial news for VICL dated on 2015-01-14: US Stock Futures Slip; JPMorgan Earnings In Focus

Financial news for VICL dated on 2015-01-14: Vical, AnGes Announce Collaboration to Develop Therapy for Ebola Virus Disease

Financial news for VICL dated on 2014-12-11: US Stock Futures Edge Higher Ahead Of Retail Sales, Jobless Claims Data

Financial news for VICL dated on 2014-12-11: Vical Completes Enrollment In Its Therapeutic HSV-2 Vaccine Clinical Trial

Financial news for VICL dated on 2014-11-17: Events for the Week of Nov. 17-21, 2014

Financial news for VICL dated on 2014-10-30: Vical Incorporated Reports Q3 EPS of \$(0.05), Inline; Revenue of \$3.44M vs \$2.50M Est

Financial news for VICL dated on 2014-10-13: Vical Shares Spike to High; Being Mentioned as Ebola Play

Financial news for VICL dated on 2014-10-08: Vical Announces Six U.S. Patents for HSV-2 Vaccines

Financial news for VICL dated on 2014-10-01: Vical Shares Spike Higher; Note Being Passed Around Indicating VICL, NIH Developing Needle-Free DNA Vaccine for Some Ebola Strains

Financial news for VICL dated on 2014-07-31: Vical Reports Q2 EPS of \$(0.05), Inline; Revenue of \$4.51M vs \$1.90M Est

Financial news for VICL dated on 2014-06-23: Events Scheduled for Week of Jun 23rd to Jun 27th, 2014

Financial news for VICL dated on 2014-05-01: Vical Reports Q1 EPS of \$(0.04) vs \$(0.05) Est; Revenue of \$2.45M vs \$1.60M Est

Financial news for VICL dated on 2014-04-15: Vical Files Prospectus for Up to \$25M Stock

Financial news for VICL dated on 2014-02-12: Vical .Reports Q4 EPS of \$(0.03) vs \$(0.09) Est; Revenue of \$3.15M vs \$1.54M Est

Financial news for VICL dated on 2014-01-10: Vical Shares Move Higher; May be Attributed to Street.com Report

Financial news for VICL dated on 2013-12-17: Vical Announces Initiation of Phase 1/2 Trial of a Therapeutic HSV-2 Vaccine for Genital Herpes

Financial news for VICL dated on 2013-12-16: Stocks Hitting 52-Week Lows

Financial news for VICL dated on 2013-12-10: Astellas, Vical Initiate Phase 2 Trial of ASP0113 Vaccine in Solid Organ Transplant Recipients

Financial news for VICL dated on 2013-08-20: Option Alert: Vical December 2.5/7.5 Call Spread; 2,245 Spread Contracts @\$0.03; Currently \$1.36

Financial news for VICL dated on 2013-08-14: UPDATE: Citigroup Lowers PT on Vical on Near-Term Challenges

Financial news for VICL dated on 2013-08-14: Citigroup Maintains Buy on Vical Incorporated, Lowers PT to \$3.00

Financial news for VICL dated on 2013-08-13: UPDATE: Credit Suisse Downgrades Vical Following Allovectin Program Termination

Financial news for VICL dated on 2013-08-13: UPDATE: Canaccord Genuity Downgrades Vical Following Allovectin Failure

Financial news for VICL dated on 2013-08-13: Benzinga's Top Downgrades

Financial news for VICL dated on 2013-08-13: Credit Suisse Downgrades Vical Incorporated to Neutral, Lowers PT to \$2.00

Financial news for VICL dated on 2013-08-13: Canaccord Genuity Downgrades Vical Incorporated to Hold, Lowers PT to \$1.40

Financial news for VICL dated on 2013-08-12: Market Wrap For Monday, August 12: Stocks Close Mixed To Start Week

Financial news for VICL dated on 2013-08-12: Stifel Nicolaus Downgrades Vical Incorporated to Hold

Financial news for VICL dated on 2013-08-12: Canaccord Genuity Downgrades Vical Incorporated to Hold

Financial news for VICL dated on 2013-08-12: Stocks Hitting 52-Week Lows

Financial news for VICL dated on 2013-08-12: Morning Market Losers

Financial news for VICL dated on 2013-08-12: Benzinga's Top Pre-Market Losers

Financial news for VICL dated on 2013-08-12: Vical Says Allovectin Fails to Meet Efficacy Endpoints

Financial news for VICL dated on 2013-08-11: Vical to Report Allovectin Phase 3 Results Prior Open of Trade Monday; Hold Conference Call at 8:00 AM ET

Financial news for VICL dated on 2013-08-01: Vical Incorporated Reports Q2 EPS of \$(0.11), Inline; Revenue of \$1.46M vs \$1.69M Est

Financial news for VICL dated on 2013-08-01: Vical Projects Phase 3 Data Release in August

Financial news for VICL dated on 2013-07-30: Vical Shares Surge as Seeking Alpha Highlights Strong Results on Allovectin-7 Trial

Financial news for VICL dated on 2013-07-30: Vical Spikes Higher; May be Attributed to Seeking Alpha Post

Financial news for VICL dated on 2013-06-25: A Peek Into The Market Before The Trading Starts

Financial news for VICL dated on 2013-06-25: Vical, Astellas Initiate Phase 3 Trial of ASP0113 Cytomegalovirus Vaccine

Financial news for VICL dated on 2013-06-17: UPDATE: Brinson Patrick Initiates Vical at Market Outperform on Allovectin Potential

Financial news for VICL dated on 2013-06-17: Brinson Patrcik Initiates Coverage on Vical Incorporated at Market Outperform, Announces \$7.00 PT

Financial news for VICL dated on 2013-05-09: Vical Incorporated Reports Q1 EPS of \$(0.11), Inline; Revenue of \$1.60M vs \$2.02M Est

Financial news for VICL dated on 2013-05-06: A Peek Into The Market Before The Trading Starts

Financial news for VICL dated on 2013-05-06: Vical's Vaxfectin Enhances Preclinical Immune Responses to Baxter's Cell Culture-Derived Influenza Vaccines

Financial news for VICL dated on 2013-04-05: Stocks to Watch for April 5, 2013

Financial news for VICL dated on 2013-02-04: Vical Announces Publication of Vaxfectin Data

Financial news for VICL dated on 2013-01-02: Vical Transfers to NASDAQ Global Select Market

Financial news for VICL dated on 2012-11-07: Vical Reports Q3 EPS \$-0.09 vs \$-0.09 Est; Revenues \$2.18M vs \$1.47M Est

Financial news for VICL dated on 2012-09-21: UPDATE: Canaccord Genuity Initiates Vical at Buy on Product Platforms

Financial news for VICL dated on 2012-09-21: Canaccord Initiates Coverage on Vical at Buy, Announces PT of \$7

Financial news for VICL dated on 2012-09-13: UPDATE: Vical Rises 10% Pre-Market on Licensing Pact with Bristol-Myers Squibb

Financial news for VICL dated on 2012-09-13: Benzinga's Top Pre-Market Gainers

Financial news for VICL dated on 2012-09-13: A Peek Into The Market Before The Trading Starts

Financial news for VICL dated on 2012-09-13: Vical Signs Licensing Pact with Bristol-Myers Squibb for DNA Immunization Technology

Financial news for VICL dated on 2012-05-16: Vical Updates Herpes Simplex Vaccine Development at ASGCT Conference

Financial news for VICL dated on 2012-05-04: Vical Files \$150M Mixed Securities Shelf

Financial news for VICL dated on 2012-04-25: UPDATE: Credit Suisse Cuts PT to \$5 on Vical;

Financial news for VICL dated on 2012-04-02: Benzinga's Top Pre-Market Gainers

Financial news for VICL dated on 2012-03-28: Novel Transmission-Blocking Malaria DNA Vaccine Candidate Uses Vical's Vaxfectin(R) Adjuvant

Financial news for VICL dated on 2012-03-05: U.S. Navy Advances Dengue DNA Vaccine Using Vical's Vaxfectin(R) Adjuvant

Financial news for VICL dated on 2012-02-08: Notable Call Options Activity in Vical

Financial news for VICL dated on 2012-02-08: Vical Reports Q4 EPS \$(0.09) vs \$(0.12) Est; Revenues \$1.93M vs \$2.04M Est

Financial news for VICL dated on 2012-01-30: Vical Presents Case Study on Successful Design of Allovectin Phase 3 Melanoma Trial

Financial news for VICL dated on 2012-01-06: Vical Incorporated Prices Public Offering of Common Stock at \$3.75 per Share

Financial news for VICL dated on 2012-01-06: Stocks To Watch For January 6

Financial news for VICL dated on 2012-01-05: Vical Incorporated (Nasdaq:VICL) today announced that it intends to offer and sell shares of its common stock in an underwritten public offering. Citigroup, Credit Suisse Securities (USA) LLC and Leerink Swann LLC are acting as joint book-running managers

Financial news for VICL dated on 2012-01-05: Vical Incorporated (Nasdaq:VICL) today announced that it intends to offer and sell shares of its common stock in an underwritten public offering. Citigroup, Credit Suisse Securities (USA) LLC and Leerink Swann LLC are acting as joint book-running managers

Financial news for VICL dated on 2012-01-05: Vical Incorporated Announces Proposed Public Offering of Common Stock; No Size Given

Financial news for VICL dated on 2011-12-28: Vical Spiking Higher on Heavy Volume

Financial news for VICL dated on 2011-12-20: Notable Call Options Activity in Vical

Financial news for VICL dated on 2011-12-11: Weekly Homework: In Search Of The Santa Claus Rally (w/ Economic Calendar & Stock Radar)

Financial news for VICL dated on 2011-12-01: Global Hunter Securities Initiates Buy, \$9 PT on Vical Incorporated

Financial news for VICL dated on 2011-12-01: Global Hunter Initiates Vical at Buy, \$9 PT

Financial news for VICL dated on 2011-11-29: Vical Breaks Out on High Volume

Financial news for VICL dated on 2011-11-04: Credit Suisse Initiating Coverage on Vical

Financial news for VICL dated on 2011-11-01: Vical Inc Reports Q3 EPS \$0.22 vs \$0.15 Est; Revenues \$26.6M vs \$20.99M Est

Financial news for VICL dated on 2011-10-03: Vical Reports Prophylactic and Therapeutic Efficacy With Herpes Simplex Vaccines in Guinea Pig Model

Financial news for VICL dated on 2011-09-22: Allovectin(R) Demonstrates Synergistic Efficacy With Anti-CTLA-4 Antibody in Melanoma Animal Model

Financial news for VICL dated on 2011-09-19: A Peek Into The Market Before The Trading Starts

Financial news for VICL dated on 2011-09-19: Vical Announces Key International Patents for Vaxfectin Adjuvant

Financial news for VICL dated on 2011-08-19: Notable Call Options Activity in Vical

Financial news for VICL dated on 2011-07-15: Rodman & Renshaw Reiterates Vical Market Outperform, \$6 PT

Financial news for VICL dated on 2011-07-14: Vical Resumes Trading Up \$0.55 After-Hours

Financial news for VICL dated on 2011-07-14: PREVIEW: Vical Incorporated to Resume Trading at 4:30 p.m.

Financial news for VICL dated on 2011-07-14: Vical and Astellas Announce Worldwide License Agreements for TransVax(TM) Cytomegalovirus Vaccine

Financial news for VICL dated on 2011-07-07: High-Flying Breakout Plays for 7/7

Financial news for VICL dated on 2011-05-12: Vical Incorporated Up 18% On Heavy Volume (VICL)

Financial news for VICL dated on 2011-05-12: Top Percentage Gainers and Losers as of 2pm 5/12/11 (DSCO, OXGN, QCOR, QTWW, SNSS, RPTP, VICL, ORBK, PNSN, SPMD, CLWR, DEXO, CCIH, TNGN, NQ, SYMX, BAC, INTC)

Financial news for VICL dated on 2011-05-02: CEOWORLD Top 5 Analyst Calls of the

Week- DNDN, INSP, MCP, SIRI, VICL

Financial news for VICL dated on 2011-05-02: Key earnings announcements for this week
ADM, PFI, K, GM- CMCSA, WFMI, CVS, V, ED

Financial news for VICL dated on 2011-04-28: List of Seven Cheap Biotech Stocks
Expected to Grow, Seeking Alpha Reports (CHTP, TLON, HGSI, VNDA, OREX, SNTA, VICL)

Financial news for VICL dated on 2011-04-27: A Peek Into The Market Before The
Trading Starts

Financial news for VICL dated on 2011-04-27: Vical Announces Encouraging H1N1
Pandemic Influenza Vaccine Phase 1 Results (VICL)

Financial news for VICL dated on 2011-04-11: A Note to All Chinese CEOs: Knock it Off
or Die! (PUDA, LLEN, CGA, CHNG, VICL)

Financial news for VICL dated on 2011-02-10: Vical Reports Q4 Loss of \$0.09 per share

Financial news for VICL dated on 2010-09-24: Benzinga's Top Pre-Market NASDAQ Losers
(VICL, FINL, CJBK, KUTV)

Financial news for VICL dated on 2010-09-24: Vical Incorporated Prices Public
Offering at \$2.25 per Share (VICL)

Financial news for VICL dated on 2010-09-23: Vical Incorporated Announces Proposed
Public Offering

Financial news for VICL dated on 2010-09-22: Shares Of Vical Dive After Clinical
Trial Ineffective

Financial news for VICL dated on 2010-09-22: Vical Downgraded to Hold (VICL)

Financial news for VICL dated on 2010-09-22: Benzinga's Top Pre-Market NASDAQ Losers
(VICL, ADBE, PMCS, BIIB)

Financial news for VICL dated on 2010-05-12: Benzinga's Top Pre-Market Gainers (SMTX,
NLST, ACHN, AEZS, VICL)

Financial news for VICL dated on 2010-04-22: Benzinga's Top Pre-Market Gainers (LIOX,
SBCF, AUTH, NVAX, VICL)

Financial news for VICL dated on 2010-03-21: How Will Obama-Care Play Into The
Markets And ETFs?

Financial news for VICL dated on 2010-01-11: Vical Inc. (VICL) Continues To Move In A
Congestion Zone

Financial news for VICL dated on 2009-12-29: Benzinga's Top Pre- Market Gainers
(STEC, VVUS, AIG, VICL, OSIS, AMZN, ASML)

Financial news for VICL dated on 2009-12-28: Benzinga's News Roundup (CALM, CGEN,
VICL, TOBC, TEG, ACTU)

Financial news for VICL dated on 2009-11-04: Vical Incorporated (VICL) Announces
Q3 Results

Financial news for VICL dated on 2009-09-10: Vical (VICL) Says A/H1N1 Influenza
Vaccine Results in Positive Immune Response